INKT
Price:
$0.4912
Market Cap:
$19.43M
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.[Read more]
Industry
Biotechnology
IPO Date
2021-10-15
Stock Exchange
NASDAQ
Ticker
INKT
According to MiNK Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 17.71M. This represents a change of -41.89% compared to the average of 30.48M of the last 4 quarters.
The mean historical Enterprise Value of MiNK Therapeutics, Inc. over the last ten years is 214.76M. The current 17.71M Enterprise Value has changed 724.67% with respect to the historical average. Over the past ten years (40 quarters), INKT's Enterprise Value was at its highest in in the September 2021 quarter at 458.97M. The Enterprise Value was at its lowest in in the June 2020 quarter at 0.
Average
214.76M
Median
110.42M
Minimum
33.40M
Maximum
438.18M
Discovering the peaks and valleys of MiNK Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 3.46%
Maximum Annual Enterprise Value = 438.18M
Minimum Annual Increase = -74.80%
Minimum Annual Enterprise Value = 33.40M
Year | Enterprise Value | Change |
---|---|---|
2023 | 33.40M | -51.07% |
2022 | 68.25M | -38.19% |
2021 | 110.42M | -74.80% |
2020 | 438.18M | 3.46% |
The current Enterprise Value of MiNK Therapeutics, Inc. (INKT) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
70.69M
5-year avg
214.76M
10-year avg
214.76M
MiNK Therapeutics, Inc.’s Enterprise Value is less than Affimed N.V. (22.90M), less than ImmunoGen, Inc. (8.19B), less than Adaptimmune Therapeutics plc (58.35M), less than Sangamo Therapeutics, Inc. (487.19M), less than Day One Biopharmaceuticals, Inc. (859.59M), less than Acumen Pharmaceuticals, Inc. (103.15M), less than X4 Pharmaceuticals, Inc. (79.21M), less than Inozyme Pharma, Inc. (215.58M), less than VectivBio Holding AG (848.58M), less than Terns Pharmaceuticals, Inc. (234.86M), greater than HOOKIPA Pharma Inc. (-37325309.00), greater than Kineta, Inc. (6.78M), less than Candel Therapeutics, Inc. (383.29M), greater than Forte Biosciences, Inc. (11.43M), greater than AlloVir, Inc. (-64850850.00), less than Monte Rosa Therapeutics, Inc. (356.78M), less than Design Therapeutics, Inc. (323.81M), greater than Werewolf Therapeutics, Inc. (-16084776.00), less than Ikena Oncology, Inc. (43.80M), less than Stoke Therapeutics, Inc. (467.23M),
Company | Enterprise Value | Market cap |
---|---|---|
22.90M | $18.12M | |
8.19B | $8.73B | |
58.35M | $150.46M | |
487.19M | $498.67M | |
859.59M | $1.28B | |
103.15M | $106.34M | |
79.21M | $98.42M | |
215.58M | $193.36M | |
848.58M | $1.06B | |
234.86M | $503.69M | |
-37325309.00 | $19.60M | |
6.78M | $7.05M | |
383.29M | $383.82M | |
11.43M | $27.79M | |
-64850850.00 | $52.01M | |
356.78M | $438.66M | |
323.81M | $351.62M | |
-16084776.00 | $69.96M | |
43.80M | $80.59M | |
467.23M | $614.95M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like MiNK Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like MiNK Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is MiNK Therapeutics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for MiNK Therapeutics, Inc. (INKT)?
What is the 3-year average Enterprise Value for MiNK Therapeutics, Inc. (INKT)?
What is the 5-year average Enterprise Value for MiNK Therapeutics, Inc. (INKT)?
How does the current Enterprise Value for MiNK Therapeutics, Inc. (INKT) compare to its historical average?